BioPharmSignal logoBioPharmSignal

Biotech News

Medpace Holdings, Inc. Reports Third Quarter 2025 Results

Medpace (MEDP)MedpaceEarnings

Revenue of $659.9 million in the third quarter of 2025 increased 23.7% from revenue of $533.3 million for the comparable prior-year period, representing a backlog conversion rate of 23.0%. Net new business awards were $789.6 million in the third quarter of 2025, representing an increase of 47.9%

Related news

MEDPMedpace2025-09-23 20:05 EST

Medpace Holdings, Inc. to Report Third Quarter 2025 Financial Results on October 22, 2025

MEDPMedpace2026-07-22 20:15 EST

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

View all latest news

Medpace

Full-Service Clinical Research Medpace is a global contract research organization providing Phase 1 through Phase 4 clinical-development services to biotechnology, pharmaceutical and medical-device companies. Therapeutic and Scientific Expertise The company uses physician leadership and therapeutic-area specialists to support protocol...

Recent company news

MEDPMedpace2026-07-22 20:15 EST

Medpace Holdings, Inc. Reports Second Quarter 2026 Results

MEDPMedpace2026-06-16 20:23 EST

Medpace Holdings, Inc. to Report Second Quarter 2026 Financial Results on July 22, 2026

MEDPMedpace2026-04-22 20:15 EST

Medpace Holdings, Inc. Reports First Quarter 2026 Results

MEDPMedpace2026-03-24 20:05 EST

Medpace Holdings, Inc. to Report First Quarter 2026 Financial Results on April 22, 2026

MEDPMedpace2026-02-09 21:15 EST

Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Results

Stock data

Close
620.75 USD
Market cap
12.73B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States